[go: up one dir, main page]

NO20064811L - 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase - Google Patents

4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase

Info

Publication number
NO20064811L
NO20064811L NO20064811A NO20064811A NO20064811L NO 20064811 L NO20064811 L NO 20064811L NO 20064811 A NO20064811 A NO 20064811A NO 20064811 A NO20064811 A NO 20064811A NO 20064811 L NO20064811 L NO 20064811L
Authority
NO
Norway
Prior art keywords
inhibitor
compound
thiophen
piperidin
aminomethyl
Prior art date
Application number
NO20064811A
Other languages
English (en)
Norwegian (no)
Inventor
Mark Czekaj
Adam W Sledeski
Zhongli Gao
Larry Davis
Julian Levell
El-Bdaoui Haddad
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20064811L publication Critical patent/NO20064811L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20064811A 2004-03-26 2006-10-23 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase NO20064811L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55692704P 2004-03-26 2004-03-26
PCT/US2005/009899 WO2005097780A1 (en) 2004-03-26 2005-03-24 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Publications (1)

Publication Number Publication Date
NO20064811L true NO20064811L (no) 2006-10-23

Family

ID=34964263

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064811A NO20064811L (no) 2004-03-26 2006-10-23 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase

Country Status (25)

Country Link
US (1) US20070142435A1 (es)
EP (1) EP1737848A1 (es)
JP (1) JP2007530580A (es)
KR (1) KR20060130682A (es)
CN (1) CN1956978A (es)
AR (1) AR048336A1 (es)
AU (1) AU2005230934A1 (es)
BR (1) BRPI0509245A (es)
CA (1) CA2560649A1 (es)
CR (1) CR8603A (es)
DO (1) DOP2005000039A (es)
EC (1) ECSP066878A (es)
IL (1) IL178031A0 (es)
MA (1) MA28547B1 (es)
MX (1) MXPA06010610A (es)
NO (1) NO20064811L (es)
PA (1) PA8627601A1 (es)
PE (1) PE20060084A1 (es)
RU (1) RU2330034C1 (es)
TN (1) TNSN06278A1 (es)
TW (1) TW200602035A (es)
UA (1) UA83738C2 (es)
UY (1) UY28821A1 (es)
WO (1) WO2005097780A1 (es)
ZA (1) ZA200607752B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071148A1 (es) * 2006-03-29 2007-12-10 Sanofi Aventis Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona
AR065616A1 (es) * 2007-03-07 2009-06-17 Sanofi Aventis Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico
WO2008115912A1 (en) * 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
WO2008121666A1 (en) * 2007-03-29 2008-10-09 Sanofi-Aventis Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone
WO2008121669A1 (en) * 2007-03-29 2008-10-09 Sanofi-Aventis 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto
CA2706391A1 (en) * 2007-11-21 2009-05-28 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AU2009206219B2 (en) 2008-01-24 2014-01-30 Soligenix, Inc. Topically active steroids for use in interstitial pulmonary fibrosis
RS54413B1 (sr) * 2008-08-22 2016-04-28 Sanofi [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
FR2955324A1 (fr) * 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
MY155682A (en) 2009-09-24 2015-11-13 Sanofi Aventis Us Llc Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof
CA2785434A1 (en) * 2009-12-23 2011-06-30 Sanofi Treatment for inflammatory bowel disease
KR20120097410A (ko) * 2009-12-23 2012-09-03 사노피 베타－트립타제 억제제로서의 인돌릴－피페리디닐 벤질아민
EP2516428A1 (en) * 2009-12-23 2012-10-31 Sanofi Tropinone benzylamines as beta-tryptase inhibitors
AR080255A1 (es) * 2010-02-24 2012-03-21 Sanofi Aventis Tratamiento de afecciones alergicas dermatologicas. composicion farmaceutica
SG2014010417A (en) 2011-10-07 2014-06-27 Takeda Pharmaceutical 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
TWI778018B (zh) * 2017-02-10 2022-09-21 美商建南德克公司 抗類胰蛋白酶抗體、其組合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227630B1 (hu) * 2000-05-22 2011-10-28 Aventis Pharma Inc Arilmetilamin-származékok triptáz gátlóként való alkalmazásra és ezeket tartalmazó gyógyszerkészítmények
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds

Also Published As

Publication number Publication date
UY28821A1 (es) 2005-10-31
PA8627601A1 (es) 2006-01-23
DOP2005000039A (es) 2005-10-31
UA83738C2 (en) 2008-08-11
IL178031A0 (en) 2006-12-31
PE20060084A1 (es) 2006-03-09
TNSN06278A1 (en) 2007-12-03
AU2005230934A1 (en) 2005-10-20
ZA200607752B (en) 2008-05-28
CR8603A (es) 2007-06-08
KR20060130682A (ko) 2006-12-19
BRPI0509245A (pt) 2007-09-11
TW200602035A (en) 2006-01-16
RU2006137717A (ru) 2008-05-10
ECSP066878A (es) 2006-11-24
US20070142435A1 (en) 2007-06-21
CN1956978A (zh) 2007-05-02
WO2005097780A1 (en) 2005-10-20
EP1737848A1 (en) 2007-01-03
MXPA06010610A (es) 2006-12-15
AR048336A1 (es) 2006-04-19
RU2330034C1 (ru) 2008-07-27
MA28547B1 (fr) 2007-04-03
JP2007530580A (ja) 2007-11-01
CA2560649A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
NO20064811L (no) 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
RU2328283C2 (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
JP2005532372A5 (es)
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
WO2010022196A3 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
DE69927497D1 (de) Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklylamidverbindungen
SE0102440D0 (sv) New compound
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application